ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
ProKidney Corp.NASDAQ: PROK
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $3.79M (cash outflow) rose 233.5% year over year, ahead of the -39.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 34.2% from the prior quarter. Over 3 fiscal years it compounded at +101.9% a year.
Context
- Capital expenditures amounted to 1701.7% of revenue in FY2025, down 37126.0 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +233.5% holds above the trailing-twelve-month pace of -39.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (15.2M) USD
- Year-over-year change
- +48.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.2M) | +48.5% |
| FY2024 | 2024-12-31 | (29.51M) | +13.7% |
| FY2023 | 2023-12-31 | (34.2M) | -1752.5% |
| FY2022 | 2022-12-31 | (1.85M) | +64.4% |
| FY2021 | 2021-12-31 | (5.19M) | — |
Capital Expenditures vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 capital expenditures of $17.85M is the 2nd largest of the 7 companies compared; the peer median is $312.09K.
- Its year-over-year change of -39.9% is the 4th highest of 6, against a peer median of -13.1%.
- Capital expenditures amounts to 2007.4% of revenue for PROK, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $18.86M | -13.1% | +27.0% | 2.9% | |
| LTM Mar 2026 | $17.85M | -39.9% | +101.9% | 2007.4% | |
| LTM Mar 2026 | $1.24M | +4.2% | +200.5% | 0.3% | |
| LTM Mar 2026 | $588K | -49.6% | -26.1% | 2.9% | |
| LTM Mar 2026 | $36.19K | +29.2% | -21.0% | — | |
| LTM Mar 2026 | $16K | -80.5% | +128.9% | — | |
| LTM Dec 2024 | $0 | — | — | — | |
| Peer median (excluding PROK) | $312.09K | -13.1% | +27.0% | 2.9% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (55.15M) | (148.14M) | (135.45M) | (163.34M) | (151.61M) |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 699K | 74.47M | 30.85M | 29.37M | 25.34M |
| Change in Working Capital | 2.16M | (6.46M) | 16.67M | 3.96M | 1.28M |
| Accounts Receivables | 0 | 0 | (1.38M) | (1.07M) | 1.32M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 5K | 494K | 11.64M | 11.59M | (5.92M) |
| Other Working Capital | 2.16M | (6.95M) | 6.41M | (6.56M) | 5.88M |
| Other Non-Cash Items | 0 | 0 | (6M) | (1.78M) | (1.7M) |
| Operating Cash Flow | (50.3M) | (77.09M) | (90.07M) | (126.35M) | (120.12M) |
| Capital Expenditures | (5.19M) | (1.85M) | (34.2M) | (29.51M) | (15.2M) |
| Acquisitions (Net) | 1K | 108K | 0 | 0 | 18.22M |
| Purchases of Investments | 0 | 0 | (471.6M) | (324.02M) | (217.08M) |
| Sales of Investments | 0 | 0 | 175.82M | 373.95M | 318.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.19M) | (1.74M) | (329.98M) | 20.41M | 103.97M |
| Debt Repayment | (30K) | (32K) | (52K) | (54K) | (26K) |
| Common Stock Issued | 71.5M | 6.05M | 0 | 144.32M | 25.6M |
| Common Stock Repurchased | 0 | 0 | (9.5M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 542.5M | 0 | 140K | 0 |
| Financing Cash Flow | 71.47M | 548.52M | (9.55M) | 144.41M | 25.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.98M | 469.69M | (429.6M) | 38.47M | 9.42M |
| Free Cash Flow | (55.49M) | (78.94M) | (124.27M) | (155.86M) | (135.31M) |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.